Yibai Pharmaceutical: Injectable Azacitidine Receives Drug Registration Certificate

MetaMuskRat · 2026-03-27T11:52:04+00:00

People's Financial News, March 27 — Yibai Pharmaceutical (600594) announced on March 27 that the company recently received the "Drug Registration Certificate" for Azacitidine for Injection, approved and issued by the National Medical Products Administration. Azacitidine for Injection is indicated for the treatment of intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS); chronic myelomonocytic leukemia (CMML); and adult patients with acute myeloid leukemia (AML) classified by the World Health Organization (WHO) with 20%–30% bone marrow blasts and multilineage dysplasia.

MetaMuskRat

2026-03-27 11:52:04

People’s Finance Network, March 27 (2024), Yibai Pharmaceutical (600594) announced on March 27. The company has recently received the Drug Registration Certificate for azacitidine for injection, approved and issued by the National Medical Products Administration. Azacitidine for injection is indicated for the treatment of intermediate-risk-2 and high-risk myelodysplastic syndromes (MDS) in the International Prognostic Scoring System (IPSS); chronic myeloid- myelomonocytic leukemia (CMML); and acute myeloid leukemia (AML) under the World Health Organization (WHO) classification, as well as adult patients with bone marrow blast percentages of 20%—30% with multilineage dysplasia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.